Business Wire

TECKRO

20.5.2021 15:06:47 CEST | Business Wire | Press release

Share
Teckro Expands Its Leadership Position in Clinical Trials With New Hires Malia Lewin and Silvina Baudino to Scale Its Global Market Strategy

Teckro , creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among study stakeholders, today announces two key hires: Malia Lewin as global head of strategy and Silvina Baudino to lead the Teckro site strategy. They are the latest experienced veterans to join Teckro’s leadership team.

Other notable hires since the start of the year, include:

  • Former Veeva Systems sales leaders Ciaran Avitabile and Jeremy Schwarz join as Teckro global head and US head of sales, respectively;
  • Previous Salesforce solution engineering leader Brian Sharkey joins to build Teckro’s global solution consulting function;
  • Cheryl Murphy, with 20+ years of experience in the pharmaceutical industry, joins as Teckro VP of customer engagement and delivery where she will lead operational excellence for a world-class customer experience.

Malia Lewin to Lead Teckro’s Strategy for Optimal Market and Product Fit

Malia Lewin has nearly 20 years of experience in the biopharma industry, serving in a variety of roles to champion new ideas, innovation and technological advancements in life sciences. Most recently, Malia was chief business officer at CherryCircle Software, a maker of cloud-based software for pharmaceutical manufacturing. Among her other roles, she served as global director of oncology strategy at Veeva Systems.

Malia says, “While clinical research pushes forward incredible scientific advancements, the management of clinical trial operations is woefully behind. This creates friction that needlessly impacts the time and cost of delivering new treatments. Teckro’s platform changes the game by allowing a seamless flow of vital information between sites and sponsors. This enables faster, safer, more efficient trials and an improved path for life-saving treatments to people around the world. ”

Silvina Baudino to Champion Teckro Requirements for Sites’ Needs

Also joining Teckro’s strategy team, Silvina Baudino brings more than 20 years of clinical trial industry experience, most recently as director of strategic site networks for IQVIA. Her career has encompassed a diverse range of responsibilities, including building and implementing innovative site-centric delivery models as well as creating strategies to improve quality and accessibility to clinical trials for patients globally.

“While public awareness and appreciation for clinical research improved with the pandemic, research site staff are struggling to work through backlogs of trials that were put on hold or delayed due to COVID-19,” Silvina explains. “Teckro is uniquely positioned to help site staff manage their demanding workloads to deliver the best outcomes for patients and preserve the quality of the research data.”

CEO Gary Hughes reflects on the current strength of Teckro, saying: “The depth of the expertise of our leadership team is testament to the belief in Teckro’s mission and our positive impact on clinical trials operations. This all-star team of leaders gives confidence to the rest of our staff, prospective employees, and our customers that we can continue to modernize and simplify clinical operations and accelerate the pace of clinical research.

Watch this short Q&A with Malia and Silvina to hear their thoughts on joining Teckro on International Clinical Trials Day and how they believe the future of clinical trials will evolve.

About Teckro

Teckro’s cloud-based clinical trial platform connects research sites, monitors and study teams with access to critical information, real-time decision support, and vital insights into clinical operations and trial performance. Teckro is used at more than 20,000 research sites and by thousands of investigators around the world. The company works with six out of the top 10 pharmaceutical companies as well as emerging biotechs. A number of trials run on Teckro are now starting to report success metrics in meeting endpoints, and others have been granted priority review by regulators in the US and Europe.

More Information:

Link:

ClickThru

Social Media:

https://www.facebook.com/teckroofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release

Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins

Grafana Labs Named a Leader in 2026 Gartner® Magic Quadrant™ for Observability Platforms and Positioned Furthest in Completeness of Vision15.7.2026 20:21:00 CEST | Press release

Named a Leader for the third consecutive year and placed furthest in vision for the second year in a row, the company has had a landmark year of innovation as observability becomes essential infrastructure for teams building and running AI at scale. Grafana Labs, the company behind the open observability cloud, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, and positioned furthest on the Completeness of Vision axis for the second year running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715814984/en/ 2026 Gartner® Magic Quadrant™ for Observability Platforms We believe this placement reflects where the market is headed: toward open, composable observability that helps teams in the AI era understand systems that are increasingly complex and agentic, and rapidly scaling thanks to AI-assisted engineering. A Platform Built for the AI Era

Spectro Cloud Raises $100 Million Series D to Help Customers Move AI Infrastructure Into Production Across Enterprise, Public Sector, Neocloud and Sovereign Cloud Environments15.7.2026 18:20:00 CEST | Press release

Growth Equity at Goldman Sachs Alternatives leads oversubscribed round with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus as organizations look to turn AI silicon into business outcomes Spectro Cloud, a leading provider of AI infrastructure management software, today announced it has raised more than $100 million in an oversubscribed Series D funding round led by Growth Equity at Goldman Sachs Alternatives, with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus. The new funding brings Spectro Cloud’s total capital raised to $260 million and will accelerate the company’s mission to help enterprises, public sector organizations, neoclouds and sovereign clouds build and operate production AI infrastructure with greater control over cost, security and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715551858/en/ Spectro Cloud raises $

K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 16:00:00 CEST | Press release

New NIQ data shows K-Beauty value sales rose 53% year-over-year and 131% over two years, underscoring how regional beauty trends, social commerce and ingredient-led innovation are reshaping global beauty growth. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 15:00:00 CEST | Press release

Viz Neuro™ Suite, including Viz ICH™ and Viz ICH Plus™, to facilitate rapid detection and care coordination for patients with basal ganglia hemorrhage across trial sites nationwide. Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye